Production (Stage)
SAB Biotherapeutics, Inc.
SABS
$1.93
$0.126.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.07% | -2.29% | |||
| Gross Profit | -1.60% | 3.75% | |||
| SG&A Expenses | 26.01% | -28.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.41% | -10.49% | |||
| Operating Income | -7.63% | 11.50% | |||
| Income Before Tax | 54.39% | -10.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.39% | -10.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.39% | -10.10% | |||
| EBIT | -7.63% | 11.50% | |||
| EBITDA | -8.36% | 10.82% | |||
| EPS Basic | 54.39% | -9.73% | |||
| Normalized Basic EPS | 54.49% | -9.96% | |||
| EPS Diluted | 54.39% | -9.73% | |||
| Normalized Diluted EPS | 54.49% | -9.96% | |||
| Average Basic Shares Outstanding | 0.00% | 0.35% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||